Modeling the asymptomatic prevalence of SARS-CoV-2 epidemic in Italy and the ISTAT survey

objectivesAugust 3rd, 2020, the Italian National Institute of Statistics (ISTAT) presented preliminary results of seroprevalence survey on the percentage of individuals affected by Covid-19. The survey aims to define (within the entire population of Italy) the portion of individuals that developed an antibody response against SARS-CoV-2. For the first time one has an estimate of the asymptomatic infected population and the possibility to acknowledge its potential role in the infection spread in Italy, one of the most affected areas in Europe. The information obtained allow a particularly sensitive validation of epidemiological models which include the asymptomatic class. methodsThe present study is devoted to the construction of a model able to simulate, in a systematic way, the asymptomatic group whose relevance in the, SARS-CoV-2 epidemic, has been recently investigated and discussed. The investigation involves the description of the first epidemic outbreak in Italy as well as the predictive analysis of the ongoing second wave. In particular the possible correction to the data of the serological tests because of their sensitivity and specificity. resultsThe model: taken as an example of the models presently used, satisfactory reproduces the data of the ISTAT survey showing a relevant predictive power and relegating in a secondary position models which do not include, in the simulation, the presence of asymptomatic groups. The corrections due to the serological test sensitivity (in particular those ones depending on the symptoms onset) make the comparison between data and models less accurate. conclusionsThe predictions of the model confirm a relevant presence of asymptomatic individuals also during the second pandemic wave in Italy. The ratio of reported to unreported cases is predicted to be roughly 1:4. A more detailed knowledge of the results of the survey could allow to correct, in a relevant way, the data by means of the experimental evidences on the antibodies sensibility. The model analyses of the vaccination strategies, confirms the relevance of a massive administration with the beginning of the year to arrive at the end of the infection within August 2021.